{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:12:11Z","timestamp":1772741531370,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11095-025-04008-w","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:26:05Z","timestamp":1767900365000},"page":"395-404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of EpiIntestinal Duodenum Microtissue as an In Vitro Model for Studying Intestinal Drug Permeability, Transport, and Metabolism"],"prefix":"10.1007","volume":"43","author":[{"given":"Jonathan","family":"Cheong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Jorski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Chhin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyoum","family":"Ayehunie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Oldach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Salphati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"5","key":"4008_CR1","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0009-9236(99)70009-3","volume":"66","author":"SM Tsunoda","year":"1999","unstructured":"Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther. 1999;66(5):461\u201371.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"4008_CR2","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1002\/jps.21363","volume":"97","author":"T Mizuma","year":"2008","unstructured":"Mizuma T. Assessment of presystemic and systemic intestinal availability of orally administered drugs using in vitro and in vivo data in humans: intestinal sulfation metabolism impacts presystemic availability much more than systemic availability of salbutamol, SULT1A3 substrate. J Pharm Sci. 2008;97(12):5471\u20136.","journal-title":"J Pharm Sci"},{"issue":"1-2","key":"4008_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ijpharm.2009.05.044","volume":"378","author":"T Mizuma","year":"2009","unstructured":"Mizuma T. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm. 2009;378(1\u20132):140\u20131.","journal-title":"Int J Pharm"},{"issue":"5","key":"4008_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/0009-9236(95)90168-X","volume":"58","author":"CY Wu","year":"1995","unstructured":"Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther. 1995;58(5):492\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"4008_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jconrel.2021.05.028","volume":"335","author":"A Fedi","year":"2021","unstructured":"Fedi A, Vitale C, Ponschin G, Ayehunie S, Fato M, Scaglione S. In vitro models replicating the human intestinal epithelium for absorption and metabolism studies: a systematic review. J Control Release. 2021;335:247\u201368.","journal-title":"J Control Release"},{"issue":"6","key":"4008_CR6","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.stemcr.2018.10.019","volume":"11","author":"R Negoro","year":"2018","unstructured":"Negoro R, Takayama K, Kawai K, Harada K, Sakurai F, Hirata K, et al. Efficient generation of small intestinal epithelial-like cells from human iPSCs for drug absorption and metabolism studies. Stem Cell Reports. 2018;11(6):1539\u201350.","journal-title":"Stem Cell Reports"},{"issue":"6137","key":"4008_CR7","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1126\/science.1234852","volume":"340","author":"T Sato","year":"2013","unstructured":"Sato T, Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science. 2013;340(6137):1190\u20134.","journal-title":"Science"},{"issue":"9","key":"4008_CR8","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.15252\/embj.201490686","volume":"34","author":"KL Sinagoga","year":"2015","unstructured":"Sinagoga KL, Wells JM. Generating human intestinal tissues from pluripotent stem cells to study development and disease. EMBO J. 2015;34(9):1149\u201363.","journal-title":"EMBO J"},{"issue":"1","key":"4008_CR9","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1038\/s41598-020-63151-z","volume":"10","author":"S Yoshida","year":"2020","unstructured":"Yoshida S, Miwa H, Kawachi T, Kume S, Takahashi K. Generation of intestinal organoids derived from human pluripotent stem cells for drug testing. Sci Rep. 2020;10(1):5989.","journal-title":"Sci Rep"},{"key":"4008_CR10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.isci.2018.03.015","volume":"2","author":"LR Madden","year":"2018","unstructured":"Madden LR, Nguyen TV, Garcia-Mojica S, Shah V, Le AV, Peier A, Visconti R, Parker EM, Presnell SC, Nguyen DG, Retting KN. Bioprinted 3D primary human intestinal tissues model aspects of native physiology and ADME\/tox functions. iScience. 2018;2:156\u201367.","journal-title":"iScience"},{"issue":"2","key":"4008_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s11626-020-00526-6","volume":"57","author":"J Markus","year":"2021","unstructured":"Markus J, Landry T, Stevens Z, Scott H, Llanos P, Debatis M, Armento A, Klausner M, Ayehunie S. Human small intestinal organotypic culture model for drug permeation, inflammation, and toxicity assays. In Vitro Cell Dev Biol Anim. 2021;57(2):160\u201373.","journal-title":"In Vitro Cell Dev Biol Anim"},{"issue":"4","key":"4008_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11095-018-2362-0","volume":"35","author":"S Ayehunie","year":"2018","unstructured":"Ayehunie S, Landry T, Stevens Z, Armento A, Hayden P, Klausner M. Human primary cell-based organotypic microtissues for modeling small intestinal drug absorption. Pharm Res. 2018;35(4):72.","journal-title":"Pharm Res"},{"key":"4008_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.70000","author":"PP Chothe","year":"2025","unstructured":"Chothe PP, Whitcher-Johnstone A, Karve A, Ramsden D, Hariparsad N. Advancing predictions of oral drug absorption, CYP3A4 induction, and transporter-mediated interactions using a human primary intestinal 3D model (EpiIntestinal). Clin Pharmacol Ther. 2025. https:\/\/doi.org\/10.1002\/cpt.70000.","journal-title":"Clin Pharmacol Ther"},{"key":"4008_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12050405","author":"Y Cui","year":"2020","unstructured":"Cui Y, Claus S, Schnell D, Runge F, MacLean C. In-depth characterization of EpiIntestinal microtissue as a model for intestinal drug absorption and metabolism in human. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12050405.","journal-title":"Pharmaceutics"},{"issue":"12","key":"4008_CR15","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1080\/17460441.2017.1378176","volume":"12","author":"T Murakami","year":"2017","unstructured":"Murakami T. Absorption sites of orally administered drugs in the small intestine. Expert Opin Drug Discov. 2017;12(12):1219\u201332.","journal-title":"Expert Opin Drug Discov"},{"issue":"4","key":"4008_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1124\/dmd.117.078626","volume":"46","author":"F Weiss","year":"2018","unstructured":"Weiss F, Hammer HS, Klein K, Planatscher H, Zanger UM, Nor\u00e9n A, Wegler C, Artursson P, Joos TO, Poetz O. Direct quantification of cytochromes P450 and drug transporters-a rapid, targeted mass spectrometry-based immunoassay panel for tissues and cell culture lysates. Drug Metab Dispos. 2018;46(4):387\u201396.","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"4008_CR17","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1021\/acs.molpharmaceut.7b00364","volume":"14","author":"C Wegler","year":"2017","unstructured":"Wegler C, Gaugaz FZ, Andersson TB, Wisniewski JR, Busch D, Groer C, Oswald S, Noren A, Weiss F, Hammer HS, Joos TO, Poetz O, Achour B, Rostami-Hodjegan A, van de Steeg E, Wortelboer HM, Artursson P. Variability in mass spectrometry-based quantification of clinically relevant drug transporters and drug metabolizing enzymes. Mol Pharm. 2017;14(9):3142\u201351.","journal-title":"Mol Pharm"},{"key":"4008_CR18","doi-asserted-by":"publisher","first-page":"8759","DOI":"10.1038\/srep08759","volume":"5","author":"F Weiss","year":"2015","unstructured":"Weiss F, Schnabel A, Planatscher H, van den Berg BH, Serschnitzki B, Nuessler AK, Thasler WE, Weiss TS, Reuss M, Stoll D, Templin MF, Joos TO, Marcus K, Poetz O. Indirect protein quantification of drug-transforming enzymes using peptide group-specific immunoaffinity enrichment and mass spectrometry. Sci Rep. 2015;5:8759.","journal-title":"Sci Rep"},{"issue":"1","key":"4008_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1056-8719(01)00161-7","volume":"46","author":"M Markowska","year":"2001","unstructured":"Markowska M, Oberle R, Juzwin S, Hsu CP, Gryszkiewicz M, Streeter AJ. Optimizing Caco-2 cell monolayers to increase throughput in drug intestinal absorption analysis. J Pharmacol Toxicol Methods. 2001;46(1):51\u20135.","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"8","key":"4008_CR20","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1007\/s11095-009-9896-0","volume":"26","author":"P Matsson","year":"2009","unstructured":"Matsson P, Pedersen JM, Norinder U, Bergstrom CA, Artursson P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res. 2009;26(8):1816\u201331.","journal-title":"Pharm Res"},{"key":"4008_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14081610","author":"G Bajraktari-Sylejmani","year":"2022","unstructured":"Bajraktari-Sylejmani G, von Linde T, Burhenne J, Haefeli WE, Sauter M, Weiss J. Evaluation of PepT1 (SLC15A1) substrate characteristics of therapeutic cyclic peptides. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14081610.","journal-title":"Pharmaceutics"},{"key":"4008_CR22","first-page":"115","volume":"320","author":"CL Crespi","year":"2006","unstructured":"Crespi CL, Chang TK, Waxman DJ. CYP2C19-mediated (S)-mephenytoin 4\u2019-hydroxylation assayed by high-performance liquid chromatography with radiometric detection. Methods Mol Biol. 2006;320:115\u20139.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"4008_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1124\/jpet.103.058065","volume":"308","author":"CL Cummins","year":"2004","unstructured":"Cummins CL, Jacobsen W, Christians U, Benet LZ. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther. 2004;308(1):143\u201355.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"4008_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1124\/jpet.300.2.399","volume":"300","author":"XQ Li","year":"2002","unstructured":"Li XQ, Bjorkman A, Andersson TB, Ridderstrom M, Masimirembwa CM. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002;300(2):399\u2013407.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1-2","key":"4008_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jbbm.2006.05.002","volume":"69","author":"A Almasi","year":"2006","unstructured":"Almasi A, Fischer E, Perjesi P. A simple and rapid ion-pair HPLC method for simultaneous quantitation of 4-nitrophenol and its glucuronide and sulfate conjugates. J Biochem Biophys Methods. 2006;69(1\u20132):43\u201350.","journal-title":"J Biochem Biophys Methods"},{"key":"4008_CR26","first-page":"92","volume":"41","author":"B Paris","year":"2009","unstructured":"Paris B, Kazmi F, Buckley D, Ogilvie B, Gipson A, Parkinson A. Pitfalls in the design of CYP inhibition studies incorporating a dilution step to examine time-dependent inhibition (TDI) or metabolism-dependent inhibition (MDI). Drug Metab Rev. 2009;41:92\u20133.","journal-title":"Drug Metab Rev"},{"issue":"1","key":"4008_CR27","first-page":"14","volume":"60","author":"MF Paine","year":"1996","unstructured":"Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther. 1996;60(1):14\u201324.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"4008_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1023\/A:1018937416447","volume":"10","author":"W Rubas","year":"1993","unstructured":"Rubas W, Jezyk N, Grass GM. Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell-line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharm Res. 1993;10(1):113\u20138.","journal-title":"Pharm Res"},{"issue":"11","key":"4008_CR29","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.1021\/acs.molpharmaceut.8b00688","volume":"15","author":"EC Chen","year":"2018","unstructured":"Chen EC, Broccatelli F, Plise E, Chen B, Liu L, Cheong J, Zhang S, Jorski J, Gaffney K, Umemoto KK, Salphati L. Evaluating the utility of canine Mdr1 knockout Madin-Darby canine kidney I cells in permeability screening and efflux substrate determination. Mol Pharm. 2018;15(11):5103\u201313.","journal-title":"Mol Pharm"},{"issue":"11","key":"4008_CR30","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/j.1745-7254.2005.00166.x","volume":"26","author":"LL Chen","year":"2005","unstructured":"Chen LL, Yao J, Yang JB, Yang J. Predicting MDCK cell permeation coefficients of organic molecules using membrane-interaction QSAR analysis. Acta Pharmacol Sin. 2005;26(11):1322\u201333.","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"4008_CR31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1517\/17425255.4.4.395","volume":"4","author":"H Sun","year":"2008","unstructured":"Sun H, Chow ECY, Liu S, Du Y, Pang KS. The Caco-2 cell monolayer: usefulness and limitations. Expert Opin Drug Metab Toxicol. 2008;4(4):395\u2013411.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"4008_CR32","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/jps.22796","volume":"101","author":"A Fortuna","year":"2012","unstructured":"Fortuna A, Alves G, Soares-da-silva P, Falcao A. Optimization of a parallel artificial membrane permeability assay for the fast and simultaneous prediction of human intestinal absorption and plasma protein binding of drug candidates: application to dibenz[b,f]azepine-5-carboxamide derivatives. J Pharm Sci. 2012;101(2):530\u201340.","journal-title":"J Pharm Sci"},{"issue":"3","key":"4008_CR33","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/cpt.967","volume":"104","author":"M Drozdzik","year":"2018","unstructured":"Drozdzik M, Busch D, Lapczuk J, M\u00fcller J, Ostrowski M, Kurzawski M, Oswald S. Protein abundance of clinically relevant drug-metabolizing enzymes in the human liver and intestine: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 2018;104(3):515\u201324.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"4008_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1067\/mcp.2002.121370","volume":"71","author":"H Glaeser","year":"2002","unstructured":"Glaeser H, Drescher S, van der Kuip H, Behrens C, Geick A, Burk O, Dent J, Somogyi A, von Richter O, Griese EU, Eichelbaum M, Fromm MF. Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters. Clin Pharmacol Ther. 2002;71(3):131\u201340.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"4008_CR35","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1021\/mp500330y","volume":"11","author":"M Drozdzik","year":"2014","unstructured":"Drozdzik M, Groer C, Penski J, Lapczuk J, Ostrowski M, Lai Y, Prasad B, Unadkat JD, Siegmund W, Oswald S. Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine. Mol Pharm. 2014;11(10):3547\u201355.","journal-title":"Mol Pharm"},{"issue":"3-4","key":"4008_CR36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ejps.2006.04.010","volume":"29","author":"G Englund","year":"2006","unstructured":"Englund G, Rorsman F, R\u00f6nnblom A, Karlbom U, Lazorova L, Gr\u00e5sj\u00f6 J, Kindmark A, Artursson P. Regional levels of drug transporters along the human intestinal tract:: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci. 2006;29(3\u20134):269\u201377.","journal-title":"Eur J Pharm Sci"},{"key":"4008_CR37","doi-asserted-by":"publisher","first-page":"S195","DOI":"10.1111\/j.1365-2125.1986.tb00322.x","volume":"22","author":"RJ Dow","year":"1986","unstructured":"Dow RJ, Graham DJM. A review of the human metabolism and pharmacokinetics of nicardipine hydrochloride. Br J Clin Pharmacol. 1986;22:S195\u2013202.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"4008_CR38","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1248\/bpb.28.882","volume":"28","author":"K Nakamura","year":"2005","unstructured":"Nakamura K, Ariyoshi N, Iwatsubo T, Fukunaga Y, Higuchi S, Itoh K, Shimada N, Nagashima K, Yokoi T, Yamamoto K, Horiuchi R, Kamataki T. Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull. 2005;28(5):882\u20135.","journal-title":"Biol Pharm Bull"},{"key":"4008_CR39","unstructured":"Moon HS, Choi JS, Bang JS. Effects of ticlopidine on the bioavailability and pharmacokinetics of nicardipine after oral and intravenous administration. . Korean J Clin Pharm. 2012;22(1):1\u20138."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-04008-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-04008-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-04008-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T19:38:35Z","timestamp":1772739515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-04008-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4008"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-04008-w","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cheong, Jorski, Chhin and Salphati were employees and\/or shareholders of Genentech, Inc. or F. Hoffmann-La Roche Ltd at the time the studies were completed.\u00a0Ayehunie, Stevens and Oldach were employees of MatTek at the time the studies were completed","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}